Findings Reveal Human Proteins Are Better Drug Targets than Previously Thought
Scientists at The Scripps Research Institute (TSRI) have developed a powerful new method for finding drug candidates that bind to specific proteins.
The new method, reported in this week’s issue of Nature, is a significant advance because it can be applied to a large set of proteins at once, even to the thousands of distinct proteins directly in their native cellular environment. The TSRI researchers demonstrated the technique to find “ligands” (binding partners) for many proteins previously thought to bind poorly to small molecules that can be used to determine the functions of their protein targets and can serve as starting compounds for the development of drugs.
Among the newly discovered ligands are selective inhibitors of two caspase enzymes, which have key roles in multiple diseases but have largely eluded efforts to target them with drugs.
“Our data suggest that the human proteome is much more broadly targetable with small molecules than has been previously appreciated,” said principal investigator Benjamin F. Cravatt, chair of the Department of Chemical Physiology and member of the Dorris Neuroscience Center and Skaggs Institute for Chemical Biology at TSRI. “That opens up new possibilities for developing scientific probes and ultimately drugs.”
Putting Fragments to Use
Researchers have long sought better ways to identify small-molecule ligands for human proteins and to determine which proteins in our cells are inherently “ligandable.” Biologists typically have used complex computer algorithms to predict whether a given class of proteins can bind adequately to small molecules. Pharmaceutical researchers often won’t even try to develop drugs to target proteins that are thought unligandable. Several large protein classes are believed to be in this category, and so far only about 600 of the roughly 20,000 human proteins have been targeted successfully with FDA-approved drugs.
“There really hasn’t been a way to determine empirically, rather than theoretically, what fraction of the human proteome can be targeted by small molecules,” Cravatt said.
The new method is partly based on an approach known as fragment-based ligand discovery, which uses candidate ligand molecules about half the size of the small molecules in pill-based drugs. For initial screens to find potential ligands, such “fragment” molecules are much more efficient than drug-sized molecules, requiring much smaller libraries of compounds for a thorough search.
Cravatt’s team attached candidate fragment molecules to a class of other molecules that, when they can get close enough, react strongly with cysteine amino-acids on proteins, locking the ligands to the proteins with strong “covalent” bonds.
“You still need an affinity-based interaction, but the covalent bonding event provides a significant boost in potency,” said Keriann M. Backus, a research associate in the Cravatt laboratory who is first author of the study with TSRI Professional Scientific Collaborator Bruno Correia.
The scientists devised a screening system in which they can apply these covalent-bonding fragment molecules one by one to entire collections of proteins expressed in human cells. The method can even be used with intact, living cells in a culture dish. The system allows researchers to detect and identify which small-molecule fragments have bound covalently to which proteins in the samples and which specific sites on the proteins are responsible for binding.
Applying a small library of cysteine-reactive fragments to the proteins found in two types of human cancer cells, the scientists found that the fragments successfully “liganded” more than 750 different cysteines found on more than 600 distinct proteins—which equated to more than 20 percent of all the proteins assayed in the samples.
Many of these proteins belonged to protein classes, such as transcription factors, that have been considered virtually unligandable, and therefore “undruggable.” In fact, about 85 percent of the newly liganded proteins are not listed in a standard database of proteins with known small-molecule ligands.
“This experiment has effectively expanded what we think of as the ligandable proteome,” said Backus.
Potential to Develop Probes and Drugs
The researchers were able to confirm the accuracy of the system, for example, by showing that it can identify the known protein targets of a covalent-binding anti-cancer drug, ibrutinib.
The team also demonstrated that some of the protein-binding ligand molecules identified with the system have strong biological activity—and thus have the potential to be developed into scientific probes or drugs. Newly discovered ligands for the enzymes IDH1 and IDH2, for example, turned out to block the activity of the normal versions of the enzymes as well as the mutant versions implicated in many cancers.
In a final set of experiments, the team showed that one of its identified ligands inhibits the activities of caspase-8 and caspase-10, two enzymes that help switch on the cellular self-destruct process known as apoptosis. An excess of apoptosis is thought to contribute to neurodegenerative conditions such as Alzheimer’s and Huntington’s disease, as well as the brain damage occurring in the aftermath of strokes and other brain injuries. By contrast, a lack of apoptosis in certain cells is believed to contribute to cancers and autoimmune diseases. However, scientists don’t understand enough about the roles of these enzymes, since they have been largely unable to find small molecules that selectively inhibit specific caspases.
In this case, Cravatt’s team found that their initially identified anti-caspase ligand works by binding the precursor forms of caspase-8 and -10. They chemically modified the ligand into one that selectively binds just the precursor of caspase-8, and, using their two ligands as probes, were able to discover new details of how caspase-8 and -10 promote apoptosis in human T-cells.
“In essence, we demonstrated that our new platform works and that we can use the ligands it identifies to do useful biology,” said Backus.
Backus and other members of the Cravatt laboratory are now doing several further studies: optimizing many of the newly identified ligands into probes for exploring protein functions; making a more comprehensive catalogue of cysteine-containing proteins that are ligandable; and expanding the method to target other amino-acids besides cysteine.
“We will be occupied for some time following up on this development,” said Cravatt.
The Latest on: Drug discovery
via Google News
The Latest on: Drug discovery
- Drug firm to seek talks with Nobel laureate Honjo with new proposalon July 27, 2019 at 2:43 pm
Ono Pharmaceutical, which started selling the drug Opdivo in 2014, will revise its earlier plan ... But the lawyer said, "We will not file a lawsuit in August and look to see how Ono acts." The ... […]
- 10% of women with no infection have drug-resistant strains of E. coli in their gutson July 27, 2019 at 12:15 am
“The enemy is at the gate,” explains Dr. Evgeni Sokurenko, a microbiologist at University of Washington who led the research team that made the recent discovery ... “They were like a wonder drug,” ... […]
- Cancer drug data release set to power next wave of therapeutic discoveryon July 25, 2019 at 7:32 am
This week (25 July) the Genomics of Drug Sensitivity in Cancer project has released the results of four years of intense data gathering and exploration which will power genetic research into ... […]
- INmune Bio Co-Founder and CEO Presents at 17th Annual Congress of International Drug Discovery Science & Technology 2019on July 25, 2019 at 7:01 am
INmune Bio Co-Founder and CEO Presents at 17th Annual Congress of International Drug Discovery Science & Technology 2019 LA JOLLA, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: ... […]
- Drug Discovery Market Is Expected to See Growth Rate of 9.81%: Pfizer, Bayer, GlaxoSmithKline, Roche Holdingon July 23, 2019 at 4:53 am
Edison, NJ -- (SBWIRE) -- 07/23/2019 -- Drug discovery refers to the clinical process of new drug development. Drug discovery market has high growth prospects owing to growth in the clinical research ... […]
- Zebrafish Screening Platform Boosts Spinal Cord Injury Drug Discoveryon July 22, 2019 at 5:18 am
Turning the phrase “a little bait catches a large fish” on its head, a research team from the University of Lisbon is hoping to use a little fish to make a big difference in the field of spinal cord ... […]
- Newly discovered biosynthetic pathway in bacteria recipe for drug discovery and productionon July 19, 2019 at 8:57 am
Microbes are master chefs of the biomolecular world; collectively, they harbor the ability to produce a vast array of unknown substances, some of which may have therapeutic or other useful properties. ... […]
- Using PROTACs for targeted protein degradation in drug discoveryon July 19, 2019 at 4:35 am
AMSBIO has introduced a new range of homogeneous proximity assays, critical enzymes and small molecule inhibitors to assess the chemical adaptor function of Proteolysis Targeting Chimeras (PROTACs). ... […]
- A zebrafish drug screening platform boosts the discovery of novel therapeutics for spinal cord injury in mammalson July 19, 2019 at 4:01 am
Spinal cord injury (SCI) is a complex condition, with limited therapeutic options, that results in sensory and motor disabilities. To boost discovery of novel therapeutics, we designed a simple and ... […]
- Clarivate Analytics introduces Cortellis Content-as-a-Service (CaaS) to accelerate drug discovery and developmenton July 18, 2019 at 6:18 am
Plug-and-play analytic toolkits enable self-service access to continually-updated molecular biology datasets and deliver greater flexibility, efficiency and value LONDON and PHILADELPHIA, July 18 ... […]
via Bing News